Tunisia

Tunisia's life sciences ecosystem has emerged as a high-potential North African hub, strategically positioned as a gateway between Europe and the Middle East.

The nation is best known for its sophisticated pharmaceutical manufacturing sector, which currently meets approximately 70% of domestic drug demand through a robust network of local and multinational producers.

Beyond traditional medicine, Tunisia is rapidly advancing in biotechnology and biosimilars, leveraging the BiotechPole Sidi Thabet to foster specialized research and industrial scaling.

The country's medical device industry also shows significant promise, driven by competitive production costs and a growing focus on high-tech diagnostic tools and digital health solutions.

This commitment to healthcare innovation is underpinned by a strong academic research foundation, with a high density of researchers per capita contributing to global breakthroughs in genetics, oncology and infectious diseases.

Tunisia is increasingly recognized for its clinical research excellence, offering a favorable regulatory environment that makes it a preferred destination for Phase II and III clinical trials.

Furthermore, the ecosystem is bolstered by an active startup culture focused on AI-driven diagnostics and telemedicine platforms, which are supported by the nation's progressive "Startup Act."

As a leader in pharma exports, Tunisia serves as a vital supplier of quality generic drugs to the Maghreb and Sub-Saharan African markets.

Collaborative clusters like HealthCare Innovation facilitate public-private partnerships that bridge the gap between lab-scale discovery and global commercialization.

With a highly skilled workforce and modernizing healthcare infrastructure, Tunisia offers a compelling value proposition for international investors seeking sustainable growth in the Mediterranean life sciences corridor.